I am interested in
  • Check All
  • Uncheck All
  • all subtypes
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma
  • Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Rare Lymphoma
  • T-Cell Lymphoma
  • / 1 checked
  • Only show this subtype

Interested in a specific sub-type?

Filter what you see here

  • Medical Information
  • Therapies
  • About

HL

ASH 2016: HL - Checkpoint inhibitors are changing current practice

Anne Villeneuve | Dec 14, 2016 | Expert Opinion

Share this article

Related Medical Information

HL

Promising results of a new HDAC inhibitor, entinostat in phase II (ENGAGE-501)

Nov 16, 2016
HL

Promising phase II results of a novel bendamustine-containing regimen (BeGEV) as induction therapy before ASCT

Nov 15, 2016
HL

HD2000 update - ABVD or BEACOPP? Which is a better treatment option?

Nov 16, 2016

Related Licenses

Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance…

Subtype: HL

INN: plerixafor

Approval status: EMA

Setting: Newly Diagnosed

OPDIVO is indicated for the treatment of patients with classical Hodgkin Lymphoma (cHL) that has relapsed or…

Subtype: HL

INN: Nivolumab

Approval status: FDA

Setting: R/R

KEYTRUDA® 50 mg powder for concentrate for solution for infusion as monotherapy is indicated for the…

Subtype: HL

INN: Pembrolizumab

Approval status: EMA

Setting: R/R

Our partners

Our supporters

  • Terms and conditions
  • Cookie policy
  • Newsletter

© 2017 Lymphoma Hub

All content on this site is intended for healthcare professionals only.
If you are a patient or carer, please visit the Lymphoma Coalition.